(Q38129335)

29 August 2017

title

Nalmefene: a review of its use in the treatment of alcohol dependence (English)

1 reference

29 August 2017

1

Gillian M Keating

1 reference

29 August 2017

publication date

1 September 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

27

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

761-772

1 reference

The size and burden of mental disorders and other disorders of the brain in Europe 2010.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

The relation between different dimensions of alcohol consumption and burden of disease: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

A microdialysis profile of beta-endorphin and catecholamines in the rat nucleus accumbens following alcohol administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

An in vivo profile of beta-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

A microdialysis profile of Met-enkephalin release in the rat nucleus accumbens following alcohol administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

A microdialysis profile of dynorphin A(1-8) release in the rat nucleus accumbens following alcohol administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

The opioidergic-alcohol link : implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Ethanol withdrawal enhances the prodynorphin system activity in the rat nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Repeated ethanol administration induces short- and long-term changes in enkephalin and dynorphin tissue concentrations in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Ethanol alters the effect of kappa receptor ligands on dopamine release in the nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

κ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Central Opioid Receptors Differentially Regulate the Nalmefene-Induced Suppression of Ethanol- and Saccharin-Reinforced Behaviors in Alcohol-Preferring (P) Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Human pharmacology and abuse potential of nalmefene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Nalmefene: intravenous safety and kinetics of a new opioid antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Reduction in heavy drinking as a treatment outcome in alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Update on harm-reduction policy and intervention research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Epidemiology and alcohol policy in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Initial preference for drinking goal in the treatment of alcohol problems: I. Baseline differences between abstinence and non-abstinence groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Initial preference for drinking goal in the treatment of alcohol problems: II. Treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0101-Y

A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.

21 January 2018

1 reference

12 December 2020

The treatment gap in mental health care

1 reference

12 December 2020

Alcohol-use disorders

1 reference

12 December 2020

The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors

1 reference

12 December 2020

Opioid antagonists for alcohol dependence

1 reference

12 December 2020

New pharmacological treatment strategies for relapse prevention

1 reference

12 December 2020

The risks associated with alcohol use and alcoholism

1 reference

12 December 2020

Harm reduction approaches to alcohol use: health promotion, prevention, and treatment.

1 reference

12 December 2020

Binding of a new opiate antagonist, nalmefene, to rat brain membranes.

1 reference

12 December 2020

Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys.

1 reference

12 December 2020

Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism

1 reference

12 December 2020

The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats

1 reference

12 December 2020

Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies

1 reference

12 December 2020

10.1007/S40263-013-0101-Y

Identifiers

DOI

1 reference

29 August 2017

1 reference